

Freedom of Information Request	FOI 22-106	15 th March 2022
--------------------------------	------------	-----------------------------

A. How many patients have been treated with the following drugs in the past 4- months:

The Health Board is unable to provide information on the number of patients treated with specific drugs. However, please find below the quantities dispensed, across Health Board pharmacies for the period November 2021 – January 2022:

• Erenumab (Aimovig) - any disease

Type	Quantity
ERENUMAB 140 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	16
ERENUMAB 70 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	34

• Fremanezumab (Ajovy) - any disease

Type	Quantity
FREMANEZUMAB (AJOVY) 225 mg in 1.5mL Pre-Filled Pen 1 Pre-Filled Pen Pack	6

• Galcanezumab (Emgality) - any disease

Type	Quantity
GALCANEZUMAB 120 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	406

• *Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Type	Quantity
BOTULINUM TOXIN TYPE A (BOTOX) 100 units Injection 1 Vial Pack	5
BOTULINUM TOXIN TYPE A (BOTOX) 200 units Injection 1 Vial Pack	8
BOTULINUM TOXIN TYPE A (BOTOX) 50 units Injection 1 Vial Pack	1
BOTULINUM TOXIN TYPE A (DYSPORT) 300 units Injection 1 Vial Pack	13
BOTULINUM TOXIN TYPE A (DYSPORT) 500 units Injection 2 Vial Pack	14
BOTULINUM TOXIN TYPE A (XEOMIN) 100 units Injection 1 Vial Pack	13
BOTULINUM TOXIN TYPE A (XEOMIN) 200 units Injection 1 Vial Pack	12
BOTULINUM TOXIN TYPE A (XEOMIN) 50 units Injection 1 Vial Pack	13

*Please note the data above in relation to Botulinum Toxin is for Neurology only. The Health Board is unable to say how much is attributed to migraine only, to determine this, the department would have to review every patient record. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

- B. **I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine. Could you please answer the following questions:**
- **Does the trust commission/fund Botulinum Toxin treatment for migraine (Y/N)?**
Yes.
 - **Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?**
Yes.
 - **In case the trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.**
Not applicable.
 - **In case the trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.**
Not applicable.